5CV.F

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$86M	+24.0%	$-0.45	$-0.57–$-0.27	—	1
2027	$135M	+57.9%	$-0.21	$-0.26–$-0.12	—	1
2028	$185M	+36.8%	$-0.64	$-0.81–$-0.39	—	1
2029	$216M	+16.8%	$-0.55	$-0.69–$-0.33	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 6 reported quarters

Reported	Est. EPS	Actual	Surprise
2025-08-15	$-0.18	$-0.26	-43.0%
2025-05-20	$-0.18	$-0.23	-26.5%
2025-04-10	$-0.21	$-0.15	+31.3%
2024-11-12	$1.41	$1.50	+6.4%
2024-08-15	$-0.72	$-0.32	+55.1%
2024-05-23	$-0.72	$-0.31	+56.3%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
5CV.FCureVac N.V.	$3.91	+0.00%	$880M	—
2VSA.FVerastem, Inc.	$6.29	+1.65%	$553M	—
DRW3.DEDrägerwerk AG & Co. KGaA	$113.00	+0.53%	$2.1B	—
DRW8.DEDrägerwerk AG & Co. KGaA	$85.00	-1.39%	$2.1B	—
EUZ.DEEckert & Ziegler SE	$12.26	-0.73%

CureVac N.V.

CureVac N.V. is a clinical-stage biopharmaceutical enterprise focused on developing revolutionary therapeutic solutions based on messenger ribonucleic acid (mRNA) technology. The company's portfolio includes various prophylactic mRNA-based vaccine candidates. For instance, CV2CoV is currently undergoing Phase 1 clinical trials for SARS-CoV-2, while CVSQIV is in Phase 1 development against influenza. Their CV7202 vaccine, designed to combat rabies virus glycoprotein, has already completed Phase 1 clinical evaluation. Additionally, CureVac is advancing vaccines for Lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Beyond vaccines, the firm is also innovating RNA-based immunotherapies for cancer, with CV8102 in Phase 1 clinical investigation for treating cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma of the skin, head, and neck. Founded in 2000, CureVac N.V. is headquartered in Tübingen, Germany.

www.curevac.com

Employees: 825
IPO / List date: Aug 14, 2020
HQ: DE

Held by traders on TradeandTell

No one on the platform currently holds 5CV.F.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 5CV.F as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 5CV.F yet.